J Chem Inf Model - Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations.

Tópicos

{ bind(1733) structur(1185) ligand(1036) }
{ compound(1573) activ(1297) structur(1058) }
{ data(3008) multipl(1320) sourc(1022) }
{ control(1307) perform(991) simul(935) }
{ drug(1928) target(777) effect(648) }
{ take(945) account(800) differ(722) }
{ state(1844) use(1261) util(961) }
{ can(774) often(719) complex(702) }
{ group(2977) signific(1463) compar(1072) }
{ method(1969) cluster(1462) data(1082) }
{ method(1219) similar(1157) match(930) }
{ algorithm(1844) comput(1787) effici(935) }
{ import(1318) role(1303) understand(862) }
{ health(3367) inform(1360) care(1135) }
{ activ(1452) weight(1219) physic(1104) }
{ imag(2830) propos(1344) filter(1198) }
{ studi(2440) review(1878) systemat(933) }
{ problem(2511) optim(1539) algorithm(950) }
{ search(2224) databas(1162) retriev(909) }
{ howev(809) still(633) remain(590) }
{ perform(999) metric(946) measur(919) }
{ system(1050) medic(1026) inform(1018) }
{ data(2317) use(1299) case(1017) }
{ signal(2180) analysi(812) frequenc(800) }
{ use(2086) technolog(871) perceiv(783) }
{ method(2212) result(1239) propos(1039) }
{ inform(2794) health(2639) internet(1427) }
{ framework(1458) process(801) describ(734) }
{ learn(2355) train(1041) set(1003) }
{ method(984) reconstruct(947) comput(926) }
{ visual(1396) interact(850) tool(830) }
{ record(1888) medic(1808) patient(1693) }
{ research(1218) medic(880) student(794) }
{ cost(1906) reduc(1198) effect(832) }
{ use(1733) differ(960) four(931) }
{ process(1125) use(805) approach(778) }
{ detect(2391) sensit(1101) algorithm(908) }
{ model(3404) distribut(989) bayesian(671) }
{ imag(1947) propos(1133) code(1026) }
{ data(1737) use(1416) pattern(1282) }
{ system(1976) rule(880) can(841) }
{ measur(2081) correl(1212) valu(896) }
{ imag(1057) registr(996) error(939) }
{ sequenc(1873) structur(1644) protein(1328) }
{ featur(3375) classif(2383) classifi(1994) }
{ network(2748) neural(1063) input(814) }
{ imag(2675) segment(2577) method(1081) }
{ patient(2315) diseas(1263) diabet(1191) }
{ motion(1329) object(1292) video(1091) }
{ assess(1506) score(1403) qualiti(1306) }
{ treatment(1704) effect(941) patient(846) }
{ surgeri(1148) surgic(1085) robot(1054) }
{ error(1145) method(1030) estim(1020) }
{ chang(1828) time(1643) increas(1301) }
{ concept(1167) ontolog(924) domain(897) }
{ clinic(1479) use(1117) guidelin(835) }
{ extract(1171) text(1153) clinic(932) }
{ method(1557) propos(1049) approach(1037) }
{ data(1714) softwar(1251) tool(1186) }
{ design(1359) user(1324) use(1319) }
{ model(2220) cell(1177) simul(1124) }
{ care(1570) inform(1187) nurs(1089) }
{ general(901) number(790) one(736) }
{ featur(1941) imag(1645) propos(1176) }
{ case(1353) use(1143) diagnosi(1136) }
{ data(3963) clinic(1234) research(1004) }
{ studi(1410) differ(1259) use(1210) }
{ risk(3053) factor(974) diseas(938) }
{ research(1085) discuss(1038) issu(1018) }
{ model(2341) predict(2261) use(1141) }
{ perform(1367) use(1326) method(1137) }
{ studi(1119) effect(1106) posit(819) }
{ blood(1257) pressur(1144) flow(957) }
{ spatial(1525) area(1432) region(1030) }
{ model(3480) simul(1196) paramet(876) }
{ monitor(1329) mobil(1314) devic(1160) }
{ ehr(2073) health(1662) electron(1139) }
{ patient(2837) hospit(1953) medic(668) }
{ model(2656) set(1616) predict(1553) }
{ age(1611) year(1155) adult(843) }
{ medic(1828) order(1363) alert(1069) }
{ sampl(1606) size(1419) use(1276) }
{ gene(2352) biolog(1181) express(1162) }
{ first(2504) two(1366) second(1323) }
{ intervent(3218) particip(2042) group(1664) }
{ activ(1138) subject(705) human(624) }
{ time(1939) patient(1703) rate(768) }
{ patient(1821) servic(1111) care(1106) }
{ can(981) present(881) function(850) }
{ analysi(2126) use(1163) compon(1037) }
{ health(1844) social(1437) communiti(874) }
{ structur(1116) can(940) graph(676) }
{ high(1669) rate(1365) level(1280) }
{ cancer(2502) breast(956) screen(824) }
{ use(976) code(926) identifi(902) }
{ result(1111) use(1088) new(759) }
{ implement(1333) system(1263) develop(1122) }
{ survey(1388) particip(1329) question(1065) }
{ estim(2440) model(1874) function(577) }
{ decis(3086) make(1611) patient(1517) }

Resumo

The rapidly growing wealth of structural and functional information about kinase genes and kinase inhibitors that is fueled by a significant therapeutic role of this protein family provides a significant impetus for development of targeted computational screening approaches. In this work, we explore an ensemble-based, protein-centric approach that allows for simultaneous virtual ligand screening against multiple kinase genes and multiple kinase receptor conformations. We systematically analyze and compare the results of ligand-based and protein-centric screening approaches using both single-receptor and ensemble-based docking protocols. A panel of protein kinase targets that includes ABL, EGFR, P38, CDK2, TK, and VEGFR2 kinases is used in this comparative analysis. By applying various performance metrics we have shown that ligand-centric shape matching can provide an effective enrichment of active compounds outperforming single-receptor docking screening. However, ligand-based approaches can be highly sensitive to the choice of inhibitor queries. Employment of multiple inhibitor queries combined with parallel selection ranking criteria can improve the performance and efficiency of ligand-based virtual screening. We also demonstrated that replica-exchange Monte Carlo docking with kinome-based ensembles of multiple crystal structures can provide a superior early enrichment on the kinase targets. The central finding of this study is that incorporation of the template-based structural information about kinase inhibitors and protein kinase structures in diverse functional states can significantly enhance the overall performance and robustness of both ligand and protein-centric screening strategies. The results of this study may be useful in virtual screening of kinase inhibitors potentially offering a beneficial spectrum of therapeutic activities across multiple disease states.

Resumo Limpo

rapid grow wealth structur function inform kinas gene kinas inhibitor fuel signific therapeut role protein famili provid signific impetus develop target comput screen approach work explor ensemblebas proteincentr approach allow simultan virtual ligand screen multipl kinas gene multipl kinas receptor conform systemat analyz compar result ligandbas proteincentr screen approach use singlereceptor ensemblebas dock protocol panel protein kinas target includ abl egfr p cdk tk vegfr kinas use compar analysi appli various perform metric shown ligandcentr shape match can provid effect enrich activ compound outperform singlereceptor dock screen howev ligandbas approach can high sensit choic inhibitor queri employ multipl inhibitor queri combin parallel select rank criteria can improv perform effici ligandbas virtual screen also demonstr replicaexchang mont carlo dock kinomebas ensembl multipl crystal structur can provid superior earli enrich kinas target central find studi incorpor templatebas structur inform kinas inhibitor protein kinas structur divers function state can signific enhanc overal perform robust ligand proteincentr screen strategi result studi may use virtual screen kinas inhibitor potenti offer benefici spectrum therapeut activ across multipl diseas state

Resumos Similares

J Chem Inf Model - Cyclophilin A inhibition: targeting transition-state-bound enzyme conformations for structure-based drug design. ( 0,847457344404488 )
J Chem Inf Model - Design of linear ligands for selective separation using a genetic algorithm applied to molecular architecture. ( 0,841950182521562 )
J Chem Inf Model - Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. ( 0,832737110407438 )
J Chem Inf Model - EMBM - a new enzyme mechanism-based method for rational design of chemical sites of covalent inhibitors. ( 0,830162370695385 )
J Chem Inf Model - Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening. ( 0,825634786887 )
J Chem Inf Model - Identification of ligand templates using local structure alignment for structure-based drug design. ( 0,815145578179689 )
J Chem Inf Model - Characterization of small molecule binding. I. Accurate identification of strong inhibitors in virtual screening. ( 0,814992147088495 )
J Chem Inf Model - Combining dyad protonation and active site plasticity in BACE-1 structure-based drug design. ( 0,813535747118965 )
J Chem Inf Model - Predicting GPCR promiscuity using binding site features. ( 0,812673678637827 )
J Chem Inf Model - Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy. ( 0,812084650532542 )
J Chem Inf Model - Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors. ( 0,810383772145382 )
J Chem Inf Model - Fragment-based drug discovery using a multidomain, parallel MD-MM/PBSA screening protocol. ( 0,809273288982531 )
J Chem Inf Model - Molecular docking and pharmacophore filtering in the discovery of dual-inhibitors for human leukotriene A4 hydrolase and leukotriene C4 synthase. ( 0,807398027932186 )
J Chem Inf Model - Interactions of halichondrin B and eribulin with tubulin. ( 0,80518539465648 )
J Chem Inf Model - Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification. ( 0,803417991270787 )
J Chem Inf Model - Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach. ( 0,8031486305637 )
J Chem Inf Model - Effective virtual screening strategy toward covalent ligands: identification of novel NEDD8-activating enzyme inhibitors. ( 0,799505247245734 )
J Chem Inf Model - Definition of drug-likeness for compound affinity. ( 0,799279295855191 )
J Chem Inf Model - Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. ( 0,79761834140644 )
J Chem Inf Model - Virtual screening of PRK1 inhibitors: ensemble docking, rescoring using binding free energy calculation and QSAR model development. ( 0,796784239349325 )
J Chem Inf Model - Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay. ( 0,796041631803659 )
J Chem Inf Model - Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example. ( 0,795588028882289 )
J Chem Inf Model - Kinetic characterization of fragment binding in AmpC ?-lactamase by high-throughput molecular simulations. ( 0,794831275653366 )
J Chem Inf Model - Accounting for target flexibility and water molecules by docking to ensembles of target structures: the HCV NS5B palm site I inhibitors case study. ( 0,794308458341713 )
J Chem Inf Model - Alignment-independent comparison of binding sites based on DrugScore potential fields encoded by 3D Zernike descriptors. ( 0,793688521253945 )
Comput Biol Chem - Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening. ( 0,793583629167519 )
J Chem Inf Model - Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. ( 0,793199946594601 )
J Chem Inf Model - Consensus scoring approach to identify the inhibitors of AMP-activated protein kinase a2 with virtual screening. ( 0,792267897750546 )
J Chem Inf Model - Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure. ( 0,791586802194278 )
J Chem Inf Model - Protein flexibility in virtual screening: the BACE-1 case study. ( 0,791252869330338 )
J Chem Inf Model - Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: the human A2A adenosine receptor as a key study. ( 0,790855618873977 )
J Chem Inf Model - Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures. ( 0,790532540793605 )
J Chem Inf Model - Inhibitor design strategy based on an enzyme structural flexibility: a case of bacterial MurD ligase. ( 0,790375575321399 )
J Chem Inf Model - Approximating protein flexibility through dynamic pharmacophore models: application to fatty acid amide hydrolase (FAAH). ( 0,789961788041794 )
J Chem Inf Model - Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds. ( 0,786590674855426 )
J Chem Inf Model - Structural properties of non-traditional drug targets present new challenges for virtual screening. ( 0,785923861336918 )
J Chem Inf Model - How to improve docking accuracy of AutoDock4.2: a case study using different electrostatic potentials. ( 0,782103071612937 )
J Chem Inf Model - Extended template-based modeling and evaluation method using consensus of binding mode of GPCRs for virtual screening. ( 0,781363030858327 )
J Chem Inf Model - Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics. ( 0,781111954237448 )
J Chem Inf Model - Ensemble-based docking using biased molecular dynamics. ( 0,779883950575303 )
J Chem Inf Model - Prediction of substrates for glutathione transferases by covalent docking. ( 0,779583611776574 )
J Chem Inf Model - LIBSA--a method for the determination of ligand-binding preference to allosteric sites on receptor ensembles. ( 0,779460658489321 )
J Chem Inf Model - Virtual target screening: validation using kinase inhibitors. ( 0,779222802322264 )
J Chem Inf Model - The 5-HT(1A) agonism potential of substituted piperazine-ethyl-amide derivatives is conserved in the hexyl homologues: molecular modeling and pharmacological evaluation. ( 0,779184990127812 )
J Chem Inf Model - Detailed mechanism of squalene epoxidase inhibition by terbinafine. ( 0,776728176851639 )
J Chem Inf Model - Computer-aided drug design of falcipain inhibitors: virtual screening, structure-activity relationships, hydration site thermodynamics, and reactivity analysis. ( 0,775469234887462 )
J Chem Inf Model - Validation of the AmpC ?-lactamase binding site and identification of inhibitors with novel scaffolds. ( 0,77521216132846 )
J Chem Inf Model - Molecular recognition in a diverse set of protein-ligand interactions studied with molecular dynamics simulations and end-point free energy calculations. ( 0,774916425170052 )
J Chem Inf Model - Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4. ( 0,774859661840879 )
J Chem Inf Model - Novel insights of structure-based modeling for RNA-targeted drug discovery. ( 0,772471220021749 )
J Chem Inf Model - Using free energy of binding calculations to improve the accuracy of virtual screening predictions. ( 0,771728435012459 )
J Chem Inf Model - Application of docking and QM/MM-GBSA rescoring to screen for novel Myt1 kinase inhibitors. ( 0,771721380856807 )
J Chem Inf Model - The impact of molecular dynamics sampling on the performance of virtual screening against GPCRs. ( 0,771055482069689 )
J Chem Inf Model - Potential and limitations of ensemble docking. ( 0,769980404137921 )
J Chem Inf Model - S4MPLE--sampler for multiple protein-ligand entities: simultaneous docking of several entities. ( 0,768806494011516 )
J Chem Inf Model - Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase. ( 0,768220543217831 )
J Chem Inf Model - Fast protein binding site comparison via an index-based screening technology. ( 0,766473089891764 )
J Chem Inf Model - Molecular modeling of potential anticancer agents from African medicinal plants. ( 0,765407143557725 )
J Chem Inf Model - Enrichment factor analyses on G-protein coupled receptors with known crystal structure. ( 0,765029020285112 )
J Chem Inf Model - Structure-based virtual screening approach for discovery of covalently bound ligands. ( 0,764597481408943 )
J Chem Inf Model - Development of a minimal kinase ensemble receptor (MKER) for surrogate AutoShim. ( 0,764015624591939 )
J Chem Inf Model - Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model. ( 0,762420714918986 )
J Chem Inf Model - Importance of the pharmacological profile of the bound ligand in enrichment on nuclear receptors: toward the use of experimentally validated decoy ligands. ( 0,761744433909393 )
J Chem Inf Model - A molecular mechanics approach to modeling protein-ligand interactions: relative binding affinities in congeneric series. ( 0,761609183079625 )
J Chem Inf Model - Docking ligands into flexible and solvated macromolecules. 7. Impact of protein flexibility and water molecules on docking-based virtual screening accuracy. ( 0,759804224671757 )
J Chem Inf Model - Identification of the Schistosoma mansoni molecular target for the antimalarial drug artemether. ( 0,75913650020415 )
J Chem Inf Model - Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9. ( 0,758440009025151 )
J Chem Inf Model - Structure-based design technology contour and its application to the design of renin inhibitors. ( 0,758351808928133 )
J Chem Inf Model - Exploration of 3D activity cliffs on the basis of compound binding modes and comparison of 2D and 3D cliffs. ( 0,75806619922576 )
J Chem Inf Model - In silico comparison of antimycobacterial natural products with known antituberculosis drugs. ( 0,757790856028684 )
J Chem Inf Model - Insights into the role of magnesium triad in myo-inositol monophosphatase: metal mechanism, substrate binding, and lithium therapy. ( 0,757473893342824 )
J Chem Inf Model - Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction. ( 0,757059309922547 )
J Chem Inf Model - Collecting and assessing human lactate dehydrogenase-A conformations for structure-based virtual screening. ( 0,756604653608717 )
J Chem Inf Model - Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen. ( 0,756109694381155 )
J Chem Inf Model - Multi-objective evolutionary design of adenosine receptor ligands. ( 0,755023605018808 )
J. Comput. Biol. - Protein-specific scoring method for ligand discovery. ( 0,754717244150236 )
J Chem Inf Model - Chemoisosterism in the proteome. ( 0,753743114274043 )
J Chem Inf Model - Facing the challenges of structure-based target prediction by inverse virtual screening. ( 0,752537860748737 )
J Chem Inf Model - Structure-based drug design of diphenyl a-aminoalkylphosphonates as prostate-specific antigen antagonists. ( 0,751941302194613 )
J Chem Inf Model - Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase. ( 0,75190240649079 )
J Chem Inf Model - Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces. ( 0,751422195536049 )
J Chem Inf Model - Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome. ( 0,750925275151582 )
J Chem Inf Model - Virtual screening for ligands of the insect molting hormone receptor. ( 0,750388053721098 )
J Chem Inf Model - Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis. ( 0,749456931418578 )
J Chem Inf Model - Three descriptor model sets a high standard for the CSAR-NRC HiQ benchmark. ( 0,748070316749759 )
J Chem Inf Model - GRID-based three-dimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation. ( 0,747764940663844 )
J Chem Inf Model - Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures. ( 0,74670968090874 )
J Chem Inf Model - Structural insights into the molecular basis of the ligand promiscuity. ( 0,745298312583191 )
J Chem Inf Model - Knowledge-based scoring functions in drug design: 2. Can the knowledge base be enriched? ( 0,744436137148964 )
J Chem Inf Model - G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations. ( 0,743261349815418 )
J Chem Inf Model - Toward fully automated high performance computing drug discovery: a massively parallel virtual screening pipeline for docking and molecular mechanics/generalized Born surface area rescoring to improve enrichment. ( 0,743202980347717 )
J Chem Inf Model - Structure-based fragment hopping for lead optimization using predocked fragment database. ( 0,743008932079523 )
J Chem Inf Model - Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility. ( 0,741742948794066 )
Comput Biol Chem - Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. ( 0,740827542796715 )
J Chem Inf Model - A robust force field based method for calculating conformational energies of charged drug-like molecules. ( 0,740824594510925 )
J Chem Inf Model - Structural chemistry of the histone methyltransferases cofactor binding site. ( 0,74077911734684 )
J Chem Inf Model - Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction. ( 0,740442689287397 )
J Chem Inf Model - Consensus docking: improving the reliability of docking in a virtual screening context. ( 0,740188571519807 )
Comput Biol Chem - Involvement of non-polyalanine (polyA) residues in aggregation of polyA proteins: Clue for inhibition of aggregation. ( 0,739822009783526 )
J Chem Inf Model - Molecular topology applied to the discovery of 1-benzyl-2-(3-fluorophenyl)-4-hydroxy-3-(3-phenylpropanoyl)-2H-pyrrole-5-one as a non-ligand-binding-pocket antiandrogen. ( 0,739384787586915 )